SHORT COMMUNICATION

Investigation of a possible extended risk haplotype in the IL23R region associated with ankylosing spondylitis

AR Roberts1,2, M Vecellio1,2, A Cortes3,4, JC Knight2,3, CJ Cohen1,2,5 and BP Wordsworth1,2,5

The IL23R region on chromosome 1 exhibits complex associations with ankylosing spondylitis (AS). We used publicly available epigenomic information and historical genetic association data to identify a putative regulatory element (PRE) in the intergenic region between IL23R and IL12RB2, which includes two single-nucleotide polymorphisms (SNPs) independently associated with AS —rs11209026 (P = 2 × 10−7) and rs11578380 (P = 2 × 10−8). In luciferase reporter assays, this PRE showed silencer activity (P < 0.001). Haplotype and conditional analysis of 4230 historical AS cases and 9700 controls revealed a possible AS-associated extended haplotype, including the PRE and risk variants at three SNPs (rs11209026, rs11209032 and rs924080), but excluding the rs11578380 risk variant. However, the rs924080 association was absent after conditioning on the primary association with rs11209032, which, in contrast, was robust to conditioning on all other AS-associated SNPs in this region (P < 2 × 10−8). The role of this putative silencer on some IL23R extended haplotypes therefore remains unclear.

Genes and Immunity (2017) 18, 105–108; doi:10.1038/gene.2017.5; published online 6 April 2017

INTRODUCTION

Ankylosing spondylitis (AS) is the archetype of a group of inflammatory disorders, known as spondyloarthropathies, in which inflammation of the spine and sacroiliac joints is prominent.1 It is a polygenic condition for which > 100 genetic associations have now been reported.2,3 Many of the genes implicated in AS are also involved in overlapping clinical conditions, such as psoriasis and inflammatory bowel disease.4,5 The importance of the interleukin (IL)-23 pathway in AS was initially suggested by the genetic association with the IL-23 receptor (IL23R).6 Subsequently, IL23R expressing cells have been identified at sites of inflammation (enthuses) in mice with SpA.7 The first IL23R association with AS to be described was with rs11209026, a missense variant in the cytoplasmic tail that affects IL-23 R signalling.6,8 The importance of the interleukin (IL)-23 pathway in AS was initially suggested by the genetic association with the IL-23 receptor (IL23R).6 Subsequently, IL23R expressing cells have been identified at sites of inflammation (enthuses) in mice with SpA.7 The first IL23R association with AS to be described was with rs11209026, a missense variant in the cytoplasmic tail that affects IL-23 R signalling.6,8 There is also a second independent association with AS in the intergenic region between IL23R and IL12RB2 (encoding the IL12 receptor-specific β chain).9 This association is also apparent in inflammatory bowel disease and Behcet disease.4,10

Recently, we identified a regulatory enhancer between IL23R and IL12RB2 that is modulated by the AS-associated single-nucleotide polymorphism (SNP) rs11209032, which is in the region of association independent of the primary coding SNP rs11209026.11 Homozygosity for the risk allele ‘A’ at rs11209032 reduces enhancer activity and increases the proportion of IFN-γ-secreting CD4+ (Th1) cells in cases with AS. It is known that genomic regulatory elements can be complex.11 In the present study, we therefore address the possibility that there are other regulatory regions or SNPs associated with this second independent AS association signal. We have used publicly available epigenomic data (that is, ENCODE12 and Roadmap13 projects) to identify additional putative regulatory elements (PREs) overlapping this region of independent genetic association with AS. We have identified a PRE containing two SNPs associated with AS independently of rs11209026, and show that it has silencer activity in luciferase reporter assays. We have performed haplotype analysis and sequential conditional analysis to identify the likely causal variants/haplotypes. Our findings suggest that there may be complex haplotypic regulatory influences in this region, but highlight that the primary AS association is with rs11209032.

RESULTS AND DISCUSSION

We first analysed the epigenomic landscape of this region in terms of chromatin accessibility and modifications. This identified a PRE (Chr1:67,759,931-67,761,417) located 34.2 kb downstream of IL23R and 11.6 kb upstream of IL12RB2 (Figure 1a) that overlaps a region of independent association previously reported in AS (conditioned on the primary coding SNP rs11209026).3 This region exhibits DNase I hypersensitivity in Th1 and Jurkat cells but not in Th17 cells. Publicly available epigenomic data showed little or no evidence of histone modifications or transcription factor binding,13,14 but these data are only available for a limited range of conditions of cell activation. We then used luciferase reporter assays to investigate the regulatory activity of this PRE in Jurkat cells transfected with pGL4.23 plasmids containing the minimal promoter with or without relevant variants of the 1.48 kb PRE sequence inserted 5′ of this minimal promoter. Transcriptional activity was compared between the minimal promoter construct alone and the wild-type 1.48 kb PRE sequence (AS-protective ‘C variants’ at both rs924080 and rs11578380), and also for the

1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Oxford, UK; 2National Institute for Health Research Oxford Comprehensive Biomedical Research Centre, Oxford University National Health Service Foundation Trust, Oxford, UK; 3Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK and 4Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia. Correspondence: Professor BP Wordsworth, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7LD, UK.
E-mail: paul.wordsworth@nuff.edu

2These authors contributed equally to this work.

Received 18 October 2016; revised 10 February 2017; accepted 21 February 2017; published online 6 April 2017
rs924080 AS-risk ‘T’ variant and rs11578380 AS-risk ‘G’ variant (Figure 1b). The PRE from the wild-type (protective) variant showed reduced reporter activity significantly below the minimal promoter level ($P < 0.001$), suggesting silencer activity. In contrast, the rs924080 AS-risk ‘T’ variant exhibited significantly greater activity than the protective allele ($P < 0.05$), which was not significantly less than that associated with the minimal promoter alone. The AS-risk ‘G’ variant at rs11578380 also significantly increased reporter activity to a similar extent (Figure 1b).

To investigate possible regulatory effects arising from multiple SNPs in the IL23R–IL12RB2 intergenic region of association, haplotype analysis was performed using PLINK. We identified 10 haplotypes for the AS-associated SNPs rs11209026, rs11209032, rs6677188, rs924080 and rs11578380 (Table 1). The risk alleles at rs11209032 (‘A’ allele) and rs924080 (‘T’ allele) were always co-inherited on haplotypes 2 and 9 (Table 1). The relatively common haplotype 2 was significantly increased in cases (36% AS vs 32% controls, $P < 2 \times 10^{-21}$), whereas the rare haplotype 9 occurred at a frequency of only 1% in both cases and controls. The protective haplotype 7 was significantly more frequent in controls (4% AS vs 6% controls, $P < 3 \times 10^{-18}$). Together, these data suggest that the risk variants at rs11209026, rs11209032 and rs924080 might have an additive effect since those associated with AS all appear on the same haplotype (haplotype 2). In contrast, the protective variants at rs11578380 and rs6677188 were found on this haplotype, suggesting that these SNPs are unlikely to be involved in any extended haplotypic effect.

| Haplotypes | Immunochip controls ($n = 19400$), n (%) | Immunochip AS cases ($n = 8460$), n (%) | rs11209026 (risk = G) | rs11209032 (risk = A) | rs6677188 (risk = A) | rs924080 (risk = T) | rs11578380 (risk = G) | OR | P-value $^b$ |
|------------|------------------------------------------|------------------------------------------|-----------------------|-----------------------|---------------------|-------------------|---------------------|----|----------|
| 1          | 10 (0.05)                                | 0 (0.07)                                 | G                     | G                     | A                   | T                 | C                   | 1.4 | 0.5      |
| 2          | 6204 (31.98)                             | 3056 (36.12)                             | G                     | A                     | T                   | T                 | C                   | 1.5 | $< 2 \times 10^{-21}$ |
| 3          | 27 (0.14)                                | 6 (0.07)                                 | A                     | G                     | T                   | T                 | C                   | 0.5 | 0.1      |
| 4          | 2272 (11.71)                             | 929 (10.98)                              | G                     | G                     | T                   | T                 | C                   | 0.9 | 0.06     |
| 5          | 34 (0.18)                                | 11 (0.13)                                | A                     | G                     | A                   | C                 | G                   | 0.7 | 0.4      |
| 6          | 4887 (25.19)                             | 2047 (24.20)                             | G                     | G                     | A                   | C                 | G                   | 0.9 | 0.3      |
| 7          | 1224 (6.31)                              | 320 (3.78)                               | A                     | G                     | T                   | C                 | G                   | 0.6 | $< 3 \times 10^{-18}$ |
| 8          | 2718 (14.01)                             | 1202 (14.21)                             | G                     | G                     | T                   | C                 | G                   | 1.0 | 0.6      |
| 9          | 204 (1.05)                               | 98 (1.16)                                | G                     | A                     | T                   | T                 | G                   | 1.1 | 0.4      |
| 10         | 1774 (9.14)                              | 764 (9.03)                               | G                     | G                     | T                   | T                 | T                   | 1.0 | 0.7      |

Abbreviations: AS, ankylosing spondylitis; OR, odds ratio; SNP, single-nucleotide polymorphism. $^a$PLINK analysis for haplotype estimation excludes very rare haplotypes that exist in < 0.05% of the population. $^b$χ²-test performed on Immunochip cases versus controls.
To confirm the presence of independent effects from individual SNPs in this putative silencer, we next performed conditional analysis using immunochip data. The PRE contains three common SNPs (minor allele frequency > 1%), two of which previously showed strong association with AS: rs924080 \((P = 2 \times 10^{-11})\) and rs11578380 \((P = 1 \times 10^{-12})\). The associations at rs924080 \((P = 2 \times 10^{-7})\) and rs11578380 \((P = 2 \times 10^{-6})\) remained positive after conditioning on rs11209026, confirming an association independent of the coding SNP rs924080. However, this interval of independent association also includes rs11209032, as previously reported.\(^{5,11}\) After conditioning on rs11209032, the apparent associations at rs924080 and rs11578380 disappeared (Table 2). In contrast, the association with rs11209032 remained positive \((P < 1 \times 10^{-4})\) after conditioning on either rs924080 or rs11578380, thereby confirming rs11209032 as the primary association with AS in this intergenic region.

These data could also be relevant to Behcet disease with which rs924080 is strongly associated \((P < 7 \times 10^{-9})\). Behcet disease is a multisystem inflammatory disorder characterised by symptoms such as uveitis, recurrent oral ulcers, skin lesions and vasculitis; it is also strongly associated with HLA-B*51.\(^{16}\) There are occasional reports of the coexistent AS and Behcet disease, but it remains unclear whether this is incidental or overlaps as part of the extended spectrum of spondyloarthropathies, of which AS is the archetype. Patients with coexistent AS and Behcet disease tend to be positive for both HLA-B*27 (AS-associated) and HLA-B*51, suggesting that it may occur incidentally.\(^{17}\)

In conclusion, we have identified a possible silencer downstream of IL23R that includes the AS-associated SNP rs924080, which appears to modulate the functional effects of this regulatory element. We have confirmed the primary association of AS with rs11209032 in this region, but suggest that there could be a possible additional effect from rs924080 in a putative silencer on the same haplotype. Further work is required to determine the potential functional relevance of rs924080 to AS and Behcet disease.

**MATERIALS AND METHODS**

Identification of a PRE

We used the published data from genome-wide association studies in AS,\(^{3}\) and publicly available data from the ENCODE\(^{13}\) and Roadmap Epigenomics Projects,\(^{14}\) to identify a 1.48 kb PRE downstream of IL23R, which includes two SNPs that are associated with AS—rs924080 and rs11578380. We evaluated DNase I hypersensitivity sites, histone modifications and transcription factor binding-sites previously reported in this region.

Luciferase reporter assay

The relevant 1.48 kb PRE sequence (Chr1:67,759,931-67,761,417) was amplified from genomic DNA. It was cloned into TA cloning kit pCR2.1 vector (Invitrogen, Paisley, UK) and subcloned into pGL4.23(luc2/minP) reporter vector (Promega, Madison, WI, USA) as previously described.\(^{11}\) Point mutations corresponding to genetic variants (T/C) of rs924080 or (G/C) of rs11578380 were introduced (primer sequences available on request) using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA, USA). Jurkat cells (Clone E6-1, ATCC TIB-152) were cultured in RPMI supplemented with 10% foetal bovine serum, 100 units per ml penicillin, 100 units per ml streptomycin and 2 mM L-glutamine. A total of 200,000 Jurkat cells per well in 24-well plates were co-transfected with 500 ng of pGL4 construct and 10 ng of pRL-null (Promega) using GeneIn (Amsbio, Abingdon, UK). After 48 h, luciferase activity was measured using the Dual-Luciferase assay reporter system (Promega). Firefly luciferase activity was normalised relative to Renilla luciferase activity for each transfection and calculated as fold increase over pGL4.23 (luc2/minP). Four repeat experiments were performed each carried out in triplicate. Student’s t-test was used to determine statistical significance.

Haplotypic analysis

All cases and controls were of White British ancestry. IL23R–IL12RBI haplotypes were estimated for 4230 AS cases and 9700 controls from the IGAS immunochip study\(^{3}\) using PLINK v1.07. The haplotypes for rs11209026, rs11209032, rs6677188, rs924080 and rs11578380 were estimated using the --hap-freq function in PLINK v1.07.\(^{15}\) The \(\chi^2\)-test was used to determine statistical significance.

Conditional analysis

We used only the same subset of cases and controls of White British ancestry from the IGAS immunochip study to evaluate genetic associations with AS.\(^{3}\) Independent effects on genetic susceptibility at the IL23R–IL12RBI locus were identified by conditional analysis of 4230 AS cases and 9700 matched controls, as previously described.\(^{3}\) Association analysis was performed using the logistic regression function in PLINK v1.07, using the same subset of cases and controls of White British ancestry from the IGAS immunochip study to evaluate genetic associations with AS.\(^{3}\) Independent effects on genetic susceptibility at the IL23R–IL12RBI locus were identified by conditional analysis of 4230 AS cases and 9700 matched controls, as previously described.\(^{3}\)

---

**Table 2. Conditional analysis of SNP associations at IL23R–IL12RBI intergenic region**

| Position* | Conditional SNP | Risk/protective | SNP | P | OR RAF (case/control) | LD (\(I^2/D\)) with conditional SNP |
|-----------|----------------|-----------------|-----|---|----------------------|----------------------------------|
| Chr1:67706208 rs11209026 G/A | rs11209032 | \(2 \times 10^{-8}\) | 1.2 | 0.96/0.93 | 0.03/0.97 |
| | rs6677188 | \(< 3 \times 10^{-3}\) | 0.9 | 0.01/0.87 | 0.03/0.97 |
| | rs924080 | \(< 2 \times 10^{-3}\) | 0.9 | 0.07/0.94 | 0.03/0.97 |
| | rs11578380 | \(2 \times 10^{-4}\) | 1.1 | 0.04/0.94 | 0.03/0.97 |
| Chr1:67740342 rs11209032 A/G | rs11209026 | \(< 9 \times 10^{-14}\) | 0.6 | 0.37/0.33 | 0.03/0.97 |
| | rs6677188 | \(< 9 \times 10^{-14}\) | 0.6 | 0.17/1 | 0.03/0.97 |
| | rs924080 | \(< 9 \times 10^{-14}\) | 0.6 | 0.38/1 | 0.03/0.97 |
| | rs11578380 | \(< 9 \times 10^{-14}\) | 0.6 | 0.5/0.95 | 0.03/0.97 |
| Chr1:67760140 rs924080 T/C | rs11209026 | \(9 \times 10^{-14}\) | 0.6 | 0.58/0.54 | 0.03/0.97 |
| | rs11209032 | \(3 \times 10^{-6}\) | 1.2 | 0.38/1 | 0.03/0.97 |
| | rs6677188 | \(0.05\) | 1.1 | 0.43/1 | 0.03/0.97 |
| | rs11578380 | \(0.06\) | 1.1 | 0.61/0.95 | 0.03/0.97 |
| Chr1:67761365 rs11578380 G/C | rs11209026 | \(< 4 \times 10^{-14}\) | 0.6 | 0.47/0.44 | 0.03/0.97 |
| | rs11209032 | \(1 \times 10^{-5}\) | 1.2 | 0.5/0.95 | 0.03/0.97 |
| | rs6677188 | \(0.3\) | 1.0 | 0.23/0.89 | 0.03/0.97 |
| | rs924080 | \(0.1\) | 0.9 | 0.61/0.95 | 0.03/0.97 |

Abbreviations: Chr., chromosome; LD, linkage disequilibrium; OR, odds ratio; RAF, risk allele frequency; SNP, single-nucleotide polymorphism. *NCBI Build 37 human genome coordinates.
REFERENCES

1. Dougdos M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum* 1991; 34: 1218–1227.

2. Ellingham D, Jostins L, Spain SL, Cortes A, Bethune J, Han B et al. Analysis of five chronic inflammatory disease-associated variants identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet* 2016; 48: 510–518.

3. Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet* 2013; 45: 730–740.

4. Duerre RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 2006; 314: 1461–1463.

5. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet* 2008; 4: e1000041.

6. Burton PR, Clayton DG, Cardon LR, Crook D, Deloukas P, Duncanson A et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat Genet* 2007; 39: 1329–1337.

7. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J et al. IL-23 induces spondyloarthropathy by acting on ROR-y+ CD3+CD4-CD8- enthesal resident T cells. *Nat Med* 2012; 18: 1069–1076.

8. Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. *PLoS ONE* 2011; 6: e17160.

9. Di Meglio P, Villanova F, Napolitano L, Tosi I, Terranova Barberio M, Mak RK et al. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T helper17 cells and impairs Th17 responses in psoriasis patients. *J Invest Dermatol* 2013; 133: 2381–2388.

10. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. *Nat Genet* 2010; 42: 698–702.

11. Roberts AR, Vecellio M, Chen L, Ridley A, Cortes A, Knight JC et al. An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation. *Ann Rheum Dis* 2016; 75: 2150–2156.

12. Daniel B, Nagy G, Nagy L. The intriguing complexities of mammalian gene regulation: how to link enhancers to regulated genes. Are we there yet? *FEBS Lett* 2014; 588: 2379–2391.

13. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* 2012; 489: 57–74.

14. Bernstein BE, Stamatoyannopoulos JA, Costello JR, Ren B, Milosavljevic A, Meissner A et al. The NIH Roadmap Epigenomics Mapping Consortium. *Nat Biotechnol* 2010; 28: 1045–1048.

15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; 81: 559–575.

16. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behcet’s disease: a comprehensive review. *J Autoimmun* 2015; 64: 137–148.

17. Küçükşen S, Bağçaci S, Karahan AY, Şahin M, Uğurlu H. Coexistence of Behçet’s disease and ankylosing spondylitis. *Eur J Gen Med* 2013; 10: 112–114.

© The Author(s) 2017

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/